Bionor provides an update on scientific collaborations

(Oslo, Norway, 13 June 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR), today provides an update on scientific collaborations in relation to the company’s HIV immunotherapy pipeline. On 31 May 2016, the Board of Directors announced a clinical strategy with continued focus on HIV immunotherapy and functional cure, which are complex scientific areas, and best pursued through …

Read more

The peer-reviewed and highly recognized journal ‘The Lancet HIV’ has accepted the results of the REDUC Part B trial for publication

(Oslo, Norway, 9 June 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR), announced today that the positive results from the clinical trial REDUC Part B (BPC01-001) will be published for the first time in the peer-reviewed and highly recognized journalThe Lancet HIV. The manuscript, entitled “The combined effect of Vacc-4x/rhuGM-CSF vaccination and romidepsin on the HIV-1 reservoir: …

Read more

The final assay in Bionor’s REDUC trial for measuring latent HIV reservoir, Integrated HIV DNA, supports the Shock & Kill approach using Vacc-4x and romidepsin

REDUC Part B results were presented today at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) (Oslo, Norway, 23 February 2016) Bionor Pharma ASA (OSE:BIONOR), a biopharmaceutical company focused on advancing a functional cure for HIV, announces that the third and final assay for measuring latent HIV reservoir size, the primary endpoint in the …

Read more